UBS Group
NPCE icon

UBS Group’s Neuropace NPCE Stock Holding History

UBS Group’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$263K Sell
16,534
-11,269
-41% -$181K ﹤0.01% 6645
2026
Q1 		$366K Sell
27,803
-17,114
-38% -$257K ﹤0.01% 6293
2025
Q4 		$694K Sell
44,917
-20,320
-31% -$272K ﹤0.01% 5868
2025
Q3 		$673K Buy
65,237
+38,203
+141% +$360K ﹤0.01% 5878
2025
Q2 		$301K Buy
27,034
+990
+4% +$12.4K ﹤0.01% 6438
2025
Q1 		$320K Buy
26,044
+19,134
+277% +$239K ﹤0.01% 6193
2024
Q4 		$77.3K Buy
6,910
+2,825
+69% +$24.6K ﹤0.01% 7036
2024
Q3 		$28.5K Sell
4,085
-19
-0.5% -$139 ﹤0.01% 7148
2024
Q2 		$31K Buy
4,104
+2,404
+141% +$24.3K ﹤0.01% 7035
2024
Q1 		$22.4K Buy
+1,700
New +$24.2K ﹤0.01% 6877
2023
Q4 		– Sell
-55
Closed -$535 – 9714
2023
Q3 		$535 Buy
+55
New +$322 ﹤0.01% 8425
2023
Q2 		– Sell
-2,623
Closed -$12.2K – 9406
2023
Q1 		$12.2K Buy
2,623
+1,071
+69% +$4.1K ﹤0.01% 7456
2022
Q4 		$2.31K Sell
1,552
-621
-29% -$1.38K ﹤0.01% 9700
2022
Q3 		$8K Buy
+2,173
New +$10.5K ﹤0.01% 8736
2022
Q2 		– Sell
-101
Closed -$1K – 10718
2022
Q1 		$1K Sell
101
-3,602
-97% -$31.1K ﹤0.01% 9891
2021
Q4 		$38K Buy
+3,703
New +$48.1K ﹤0.01% 7173
2021
Q3 		– Sell
-2,563
Closed -$61K – 9897
2021
Q2 		$61K Buy
+2,563
New +$59.5K ﹤0.01% 6253

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

UBS Group's NPCE Position: Q2 2026 in Review

UBS Group reduced its Neuropace (NPCE) stake by 41% in Q2 2026, selling an estimated $181K and leaving 16,534 shares worth $263K. The position accounts for ﹤0.01% of the portfolio, ranked #6645.

UBS Group first reported a position in NPCE in Q2 2021 and has held it in 17 quarters since. The position peaked at $694K in Q4 2025. 113 funds tracked by Wall St. Rank hold NPCE as of Q2 2026.

  • UBS Group held 16,534 shares of Neuropace worth $263K as of Q2 2026.
  • UBS Group sold 11,269 Neuropace shares in Q2 2026, an estimated $181K.
  • Neuropace made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #6645 holding.
  • UBS Group first reported a position in Neuropace in Q2 2021 and has held it in 17 quarters since.
  • UBS Group's Neuropace position peaked at $694K in Q4 2025.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.